Current Market Access to Avsola, Inflectra and Remicade
While biosimilars Avsola and Inflectra are picking up ground, Remicade is still more advantaged, holding covered or better status for 61% of all insured lives.
NOTE: Access that requires prior authorization and/or step therapy is represented by the abbreviation (PA/ST). 274.0 million lives are covered under the pharmacy benefit.
SOURCE: MMIT Analytics, as of 7/12/21.
Related Posts

November
16
Third-Quarter 2023 Digital Health Funding, Deals Decline, but Promising Areas Exist
Read More
November
16
FDA Approves Multiple Ulcerative Colitis Agents, Bringing New Drugs, Routes of Administration to Class
Read More
November
16